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Background: Mast cell leukemia (MCL) is rare type of neoplasia with an incidence of 1% in a large series of 342
adult patients with systemic mastocytosis (SM). Chronic basophilic leukemia (CBL) is an extremely rare type of
leukemia with appearance of 7 cases in the literature.
Case presentation: A 73 year-old female patient who presented with weaknes, had a prolonged duration of
hematologic remission after treatment of her CBL by hydroxyurea (HU). Evolution of SM occurring as a second
neoplasia concurrently with relapse of de novo CBL was demonstrated by mast cells (MCs) infiltration in the bone
marrow (BM) biopsy and smear and increase in tryptase level. Transformation to MCL with simultaneous occurrance
of accelerated phase of CBL were documented by the appearance of MCs in both BM and peripheral blood (PB)
smears, antigen expressions detected by flow cytometry and spesific stains. Sequence analysis of c-kit gene revealed
c-kit exon 11 K550N mutation. Undefined associations of MCL with different mast cell morphology, increase in IL-6
level and accelerated phase of de novo CBL was described.
Conclusion: Elevations in CRP and IL-6 levels occurring with increases in basophil counts to high levels revealed
that febrile episodes with abdominal pain seen in our patient were induced by increase in IL-6 levels released from
neoplastic basophils. Neoplastic basophils with diffuse and coarse basophilic granules possibly mimic neutrophils
with toxic granules and cause wrong characterization of neoplastic basophils as neutrophils by the automated
blood cell counters and misleaded physicians.
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Mast cell leukemia (MCL) is rare type of neoplasia with an
incidence of 1% in a large series of 342 adult patients with
systemic mastocytosis (SM) [1] and accounting for <1% of
all mastocytosis in the French Referance Center for Masto-
cytosis (CEREMAST) [2]. SM associated with clonal
hematologic non-mast cell disease (SM-AHNMD) was the
second most common SM subgroup (N = 138, 40%) in this
cohort of patients [1]. Of The SM-AHNMD group, 89%
had an associated myeloid malignancy group. This group
included subgroups of, SM-myeloproliferative neoplasia
(SM-MPN), SM-chronic myelomonocytic leukemia (SM-
CMML) and SM-myelodysplastic syndrome (SM-MDS). A
significant proportion exhibited prominent eosinophilia* Correspondence: cehrelicavit@gmail.com
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unless otherwise stated.(>1.5 × 109/l), especially those with SM-MPN and 39%
harbored the FIP1L1-PDGFRA fusion [1,3]. A literature
search was performed by using PubMed database for all
proven MCL cases according to WHO criteria and 51
adult patients with MCL were detected appearing as de
novo, (n = 30) and secondary, (n = 11). The median ages
for de novo and secondary cases were 51.5 (18–78) and
35.0 (5–75) respectively. Median survival was 6 months
(0.5-98) in all adult patients seen in the literature [2].
CBL is an extremely rare type of leukemia with the ap-
pearance of seven cases in the literature [4-7]. Four of the
seven patients reported by Pardanani et al. identified by
screening of electronic data base in Mayo Clinic [4] MCL,
occuring as a second neoplasia in association with un-
defined MC morphology and de novo CBL relapse have
not been described in the World’s literature [4-7]. A case
of MCL occuring as a second neoplasia in association withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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celerated phase of de novo CBL was described.
Case presentation
A 73 year old Turkish female patient who presented
with weakness, epigastric fullness and decreased appe-
tite had a prolonged duration of hematologic remission
by the treatment of her CBL with hydroxyurea (HU)
[7]. At presentation, complete blood counts (CBC)
showed marked decrease in hemoglobin. Differential
count made by automated blood cell counter revealed
30% segmented neutrophils, 30% eosinophils, 32% lym-
phocytes and 8% monocytes. However marked baso-
philia and eosinophilia at different stages of maturation
detected by manual differential in PB smear revealed
that automated blood cell counters wrong characterized
the neoplastic basophilic cells with coarse and diffuse





1. month 3. month
(×109/L)
White Blood Cells 4.6 59.0 170.0
Basophil count 2.6 36.5 79.9
Eosinophil count - - 4.5
Mast cell count - - 28.9
Platelet 134.0 157 80.0




Seg. Basophil 46 10 10
Basophil Band 8 12 5
Basophil Meta. 3 25 14
Basophil Myelo. - 15 18
Promyelocyte - - 9
Eosinophilic series 29 6 27
Myeloblast - - -
Mast cell - - 17




IL-6 (pg/mL) ††† - 38.5
CRP (mg/dL) - 85.6 225
LDH (U/L) - 561 1221
Treatments Watch-wait HU 1 g/L
(×3 days)
leukaph. + HU 1.5 g/l (×3
days) + prednisolon 40 mg
Magnification: 160 X 135 mm
†by F.E.I.A ImmunoCAP PHADIA, N < 11.4, treshold 11.4/l : 95th percentile (Cerba La
†††by Electrochemiluminescence ECLIA Roche (N < 7).She was firstly transfused with 4 units of packed red
blood cells (rbc) for severe anemia and maintenance
therapy with HU was discontinued. Results of rutin la-
boratory studies with gastroscopy and colonoscopy failed
to reveal gastrointestinal bleeding and hemolysis.
Bone marrow (BM) aspiration showed hypercellularity,
basophilic hyperplasia, eosinophilia, increase in megakar-
yocytes and aggregates of mast cells. Suppressions in neu-
trophilic and in erythroid lineages induced by basophilic
hyperplasia and MCs infiltration were seen. BM biopsy
showed increase in megakaryocytes and eosinophils at
different stages of maturation. Increased numbers of MCs
in paratrabecular location were highlighted by immuno-
histochemical staining for CD117 and tryptase (Figure 1a,
b and c). Increase in serum level of tryptase was shown in
Table 1.
Diagnosis of SM occurring as second neoplasia concur-
rently with de novo CBL that relapsed after prolonged5. month 7. month 7,5. month 8.
month

























b. Paris France, Ref no: 887821335110 and Ref no 9197749), †† by RIA (N < 10),
Figure 1 Showing increased number of mast cells demonstrated by H&E stain in (a), immunohistochemical staining for tryptase in
(b) and D117 in (c), respectively (×20).
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white blood cell (wbc) count except for the basophilia
and eosinophilia was normal. The patient has been
watched without treatment to see the recurrence of
febrile episodes [7].
Clinical course
Results of CBC and chemistry profiles during the clinical
course were shown in Table 1.
One month later she was seen for symptoms of
anemia, without fever. CBC showed increase in wbc and
mast cell counts and decrease in Hgb. She was started
on HU 1000 mg/day, but after 3 days, developed fever
and her platelet count decreased to 63 × 109/l. The pa-
tient stopped taking HU.
About 2 months after (3. month of first presentation),
she presented with fever, abdominal pain, headache,
weakness, diarrhea and was hospitalized. Repeat CBC re-
vealed marked increase in wbc, basophil, eosinophil and
mast cell counts, and decrease in Hgb. MCs showed un-
even distribution with aggregates of 2 to 6 MCs on PB
smear as they were seen in the BM smear. MCs have
round nuclei, one or more nucleoli in immature forms
and mixed black and orange color round cytoplasmicFigure 2 Showing aggregates of mast cells containing mixed black and
basophil in (a) (wright’s stain × 100), brown color round granular cytop
staining on PB smear representing mast cells in (b) (×100).granules (Figure 2a). Her blood chemistry profiles were
normal except for elevations in C-reactive protein (CRP)
and lactate dehydrogenase (LDH). Laboratory studies
performed during the febrile attack showed normal his-
tamine, prominently increased IL-6 and elevated tryptase
levels.
Repeated BM aspiration showed hypercellularity, baso-
philic hyperplasia having diffuse, coarse basophilic gran-
ules and eosinophilia with presence of all stages of
maturation of basophilic and eosinophilic lineages, in-
cluding 2% segmented basophils, 7.5% basophlic bands,
17.5% basophilic metamyelocytes, 23.5% basophilic mye-
locytes, 1% segmented eosinophil, 4.5% eosinophilic
bands, 8.5% eosinophilic myelocytes, 8% promyelocytes,
21.5% MCs. Marked suppression in neutrophilic lineage
and moderate suppressions in erythroid and megakaryo-
cytic lineages induced by basophilic hyperplasia and
mast cell infiltrations were detected. The M:E ratio was
15.3:1. MCs exhibited uneven distribution with aggre-
gates of 2 to 6 MCs throughout the marrow fields. Rare
binuclear forms of MCs were also noted. Striking dyspla-
sia manifested as giant segmented basophils, giant baso-
philic bands, giant binuclear basophilic metamyelocytes,
frequent Pelger-Hüet anomaly (Figure 3a) and binuclearorange color round cytoplasmic granules and a giant segmented
lasmic staining demonstrated by tryptase immunohistochemical
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hypersegmented megakaryocytes, hypogranular forms
and rare megakaryoblasts were also observed.
Transformation to MCL from secondary SM occuring
concurrently with accelerated phase of CBL relapse was
detected 2 months after evolution to SM. The patient
underwent 2 consecutive prophylactic leukapheresis to
reduce to basophil count below 40 × 109/l for the
prevention of cytokine release from dead neoplastic
cells induced by chemotherapy. She was transfused with
2 units of packed rbc and the treatment was resumed
with increase in daily dose of HU to 1500 mg. Despite
prophylactic leukapheresis, she developed febrile epi-
sode 3 days after chemotherapy. Her fever returned to
normal with corticosteroid therapy, 40 mg/day, for
3 days, but she developed hematochezia due to
decrease in Plt count to 28 × 109/l. HU therapy was
discontinued and she received supportive transfusion
with plt packs and packed rbc.
The patient has received no treatment for about two
months since she has required continuous supportive plt
and rbc transfusions. Her wbc counts ranged betwen 4.5 ×
109/l and 18.3 × 109/l and Plt counts ranged between 4 ×
109/l and 25 × 109/l repectively during this period.
About 2 moths later (5. month of first presentation), she
was reevaluated for symptoms of anemia. CBC showed in-
creases in basophil, eosinophil and mast cell counts and
decrease in Hgb. Treatment with interferon alpha-2b
(INFα-2b) was considered, but could not be administered
because of persistent thrombocytopenia. She was treated
with imatinib 300 mg/day combined with HU 500 mg/day
during the ensuing month. She feld better, but decreases
in Hgb to 7 g/dl and Plt count to 20 × 109/l were noted.
Combination therapy was stopped and she was given sup-
portive plt and rbc transfusions.
Approximately, 7 weeks later (7. month), she developed
fever, abdominal pain, fatigue and her spleen was palpableFigure 3 Demonstrating basophils at various stages of maturation,gia
with mixed black and orange color round cytoplasmic granules and Pel
granular staining by peroxidase stain in peroxidase positive basophils a
myeloperoxidase negative mast cells in the BM in (b) (Peroxidase stain,4 cm below the left costal margin. CBC showed marked
increases in wbc, basophil, eosinophil and mast cell
counts and decrease in Hgb. The patient underwent 2
consecutive leukapheresis. Treatment with oral etopo-
side 50 mg/day was started, but on the thirth day of
chemotherapy she developed fever and was hospital-
ized. Repeat CBC showed a wbc of 2.3 × 109/l, Hgb
7.7 g/dl and Plt count 2 × 109/l. Oral etoposide was dis-
continued because of thrombocytopenia (2 × 109/l) and
leukopenia (2.3 × 109/l). She was treated with antibi-
otics and supportive transfusions. The patient was then
followed for 2 weeks (7.5 month) without chemother-
apy, but developed fever, abdominal pain and a rapid
increase in wbc cunt to 250 × 109/l was detected. She
was started on leukapheresis and given i.v cyclophos-
phamide 1000 mg, but despite these treatments 2 weeks
after (8.monts), her wbc count continued to climb. Her
biochemical and coagulation parameters were deterio-
rated rapidly. Repeat CBC revealed prominent increase
in wbc, basophil and mast cell counts and decreases in
Hgb and Plts. Coagulation profile revealed disseminated
intravascular coagulation (DIC) during terminal phase.
DIC was due to febrile neutropenia and infection that
resulted in septic shock. Despite supportive manage-
ments with transfusions of fresh frozen plasmas, plt
packs and packed rbc. DIC could not be controlled and
she expired 4 days after development of DIC. The
patient died 5 months after the diagnosis of MCL.
Results of laboratory studies
Toluidine blue stain on PB and BM smears demonstrated
diffuse granular metachromatic staining in the great major-
ity of cells including MCs and basophils when transform-
ation to MCL was detected. Peroxidase stain of BM smear
showed diffuse granular staining in <60% of non-erythroid
nucleated BM cells and peroxidase negative aggregates of
cells (Figure 3b). Tryptase immunohistochemical stainingnt binuclear basophilic metamyelocyte, aggregates of mast cells
ger-Huёt anomalies in (a) (Wright’s stain, ×100). Showing diffuse
nd absence of staining in aggregates of cells that representing
×100).
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automated staining apparatus and Ventana-Cell Marque-
G3 mouse monoclonal antibody. Tryptase immunohisto-
chemical staining of PB smear showed brown color round
granular cytoplasmic staining in the aggregates of cells
(Figure 2b).
Flow cytometric analysis of BM mononuclear cells
(MNCs) showed that antigen expressions were positive for
CD10 (dim), CD11c (dim), CD13, CD15, CD22 (dim),
CD33, CD38, CD45, CD123, IgD receptor and CD117 and
negative for HLA-DR,CD7 and CD71.
Cytogenetic and molecular studies
Chromosome analysis was performed on 20 metaphases
and abnormal karyotype was detected in six out of 20
metaphases. Cytogenetic analysis of BM cells revealed: 47,
XX,der(6)t(6;?)(q25-27;?),der(17)t(17;?)(p13;?),+mar[6] / 46,
XX[14].
Additional chromosomal materials were detected on the
long arm of chromosome 6 and on the short arm of
chromosome 17 respectively, in addition to a marker
chromosme of unknown origin.
Sequence analysis performed on amplified PCR products
of exons 9, 11,13 and 17 of c-kit gene revealed heterozy-
gote substitution of C1650A > T (K550N) on exon 11 while
wild type sequences were found in exons 9, 13 and 17
respectively. Molecular genetic studies performed by using
LSI 4q 12 Tricolor Probe failed to reveal FIP1L1-PDGFRA
fusion gene rearrangement.
Discussion
CBL is a very rare type of leukemia, because seven pa-
tients with CBL appeared in the literature [4-7]. The two
of the four cases reported as CBL by Pardanani et al. [4]
could be categorized as SM-CBL according to the WHO
major morphologic diagnostic criteria [3] as in the case
described by Lahortiga et al. [5]. Because, an abnormal
pattern of perivascular atypical mast cell infiltration were
detected by tryptase immunohistochemical staining in
these patients [4,5]. Except for the cases reported by
Lahortiga et al., Tang et al. and Cehreli et al. [5-7], flow cy-
tometric analysis of antigen expressions required for the
diagnosis of CBL were not present in four of the seven
cases because this method was not available at that time
[4]. Spesific stainings diagnostic for CBL was performed in
only one [7] of the seven cases reported in the literature
[4-7].
In our patient, MCs infiltration detected by immuno-
histochemical staining for tryptase and CD117 in the
BM biopsy (Figure 1b, c) and elevation in tryptase level
revealed evolution of SM occurring as a second neopla-
sia concurrently with de novo CBL relapse. Antigen ex-
pressions of CD10 (dim), CD11c (dim), CD13, CD15,
CD22 (dim), CD33, CD38, CD45, CD123, IgD receptorand CD117 demonstrated by flow cytometric analysis of
BM MNCs demonstrated infiltrations with basophilic
cells [8-10] and MCs and supported evolution of SM
occuring simultaneously with relapse of de novo CBL.
Evolution of SM occurring as second neoplasia concur-
rently with de novo CBL that relapsed after prolonged
duration of hematologic remission have not been seen in
the literature [1-7].
Tansformation to MCL occurring from secondary SM
with simultaneous development of accelerated phase of
CBL was documented by the appearance of aggregates
of MCs containing mixed black and orange color round
cytoplasmic granules in both PB and BM smears
(Figures 2a and 3a) in the reported patient. Marked dys-
plasia in neoplastic basophils and frequent Pelger-Hüet
anomaly (Figure 3a) were the striking feature of the BM.
Cytoplasmic granules of MCs may appear as either dark
blue to purple and even blackish in color [11,12]. Mast
cells containing mixed black and orange color round cyto-
plasmic granules demonstrated by Hayhoe and Flemans in
(figure 556) in the Colour Atlas of Haematological
Cytology [12] and also shown in (Figures 2a and 3a) of
our patient. Cytoplasmic granules may be seen on the nu-
clei of MCs.
Additionally, tryptase immunohistochemical staining
of the PB smear in our patient showed round granular
brown color cytoplasmic staining in the aggregates of
cells confirmed that these cells demonstrated tryptase
activity and represented MCs (Figure 2b). Because β-
tryptase is a natural serine protease and is the most
abundant mediator stored in the granules of mast cells
[13]. This staining method could be utilized for the dem-
onstration of undefined mast cells with atypical morph-
ology on PB smear. MCs containing mixed black and
orange color round cytoplasmic granules have not been
described in patients with MCL appeared in literature
[1-3].
Peroxidase stain showed diffuse granular staining in
the majority of cells with presence of peroxidase nega-
tive aggregates of cells in BM and PB smears also dis-
closed transformation to MCL occurring simultaneously
with accelerated phase of CBL. Because, mast cells do
not contain peroxidase and appeared as peroxidase
negative cells [14,15], but basophils have basophil perox-
idase [8] and stained with peroxidase, as seen in
Figure 3b.
Diffuse granular metachromatic staining with toluidine
blue stain on PB and BM smears was the supportive evi-
dence revealing CBL relapse with evolution to MCL in
our patient. Basophils and mast cells have electron-
dense cytoplasmic granules and produce numerous in-
flammatory mediators such as histamine that are
common to both cells and stain metachromatically with
basic dyses, toluidine blue and alcian blue [11,14].
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with simultaneous development of accelerated phase of
CBL have not been described in patients with MCL
reported in literature [1-7]. The accelerated phase of
CBL in association with MCL, showed prominent dys-
plastic changes in basophilic, eosinophilic and megakar-
yocytic lineages of the BM with frequent Pelger-Hüet
anomalies compared to the chronic phase of CBL [7].
Eosinophilia have been described in patients with CBL
appeared in the literature [4-7], but after evolution of SM
and transformation to MCL prominent eosinophilia, 5.3 ×
09/l in PB and BM were detected in our patient. Marked
eosinophilia (>1.5 × 109/l) was described in patients with
SM-AHNMD, especially in 56% of SM-MPN and 39% of
patients harbored FIP1L1-PDGFRA fusion gene [3].
FIP1L1-PDGFRA fusion gene rearrangement was found
negative in our patient.
Our patient had weight loss and has had febrile epi-
sodes with abdominal pain when basophil counts in-
creased >40.000 × 109/l before or after chemotherapies
with elevations in CRP and IL-6 levels. Although MCs
and eosinophils were shown to produce IL-6 [16], but
no febrile episodes were observed despite increases in
MC count to 3 × 109/l, eosinophil count to 5.3 × 109/l
because basophil count was 9.8 × 109/l, less than 35 ×
109/l.
In addition, molecular studies performed during chronic
phase of CBL by real time PCR in magnetic activated cell
sorting (MACS) separated basophil fraction of BM MNCs
demonstrated IL-6 gene expression in neoplastic basophils
revealed that synthesis and release of IL-6 produced by
neoplastic basophils in our patient [7].
MC activation symptoms included flushes, fever,
malaise, diarrhea and tachycardia. Many patients were
suffering from asthenia, severe weight loss and an-
orexia in 51 adult patients with MCL [2]. Elevations in
CRP and IL-6 levels occurring with increases in baso-
phil counts to high levels revealed that febrile episodes
with abdominal pain seen in our patient were induced
by increase in IL-6 levels released from neoplastic
basophils [7,17].
Literature review failed to demonstrate c-kit exon 11
K550N mutation and its effect on response to treat-
ment and prognosis in patients with SM. In a phase III
trial of imatinib mesylate for the treatment of advanced
gastrointestinal stromal tumors studied by Cancer and
Leukemia Group B and Southwest Oncology Group
(CALGB 150105) revealed that the presence of KIT
exon 11–mutant genotype (n:283) correlated with
improved treatment outcome when compared with
KIT exon 9–mutant (n:32) and wild-type (n:67) geno-
types for objective response, complete response (CR) /
partial response (PR) 71.7% v 44.4% (P .007) and 44.6%
(P .0002), respectively [18].Complete clinical and hematological remission were
obtained by the treatment with imatinib in 3 out of five
patients with SM showing eosinophilia and negative for
c-kit D816V, but the other two who did not respond to
treatment were the patients with the c-kit D816V posi-
tive. These results revealed that imatinib either inhibits
the growth-promoting role of wild type c-kit, or targets
as yet undefined a novel oncogenic kinase. [19,20]. Dur-
ing transformation to MCL associated with accelerated
phase of CBL our patient did not respond to combin-
ation treatment with imatinib and HU.
Responses to treatments during transformation to
MCL occurring with simultaneous development of ac-
celerated phase of CBL have been ineffective. Refrac-
toriness to treatments was thought possibly due to
development of resistant clones because cytogenetic
studies showed an additional chromosomal material on
the short arm of chromosome 17 where the p53 gene is
located. The patient has had rapid and downhill course
after transformation to MCL. Her biochemical and co-
agulation parameters were deteriorated rapidly and she
developed DIC during the terminal phase. Despite sup-
portive transfusions and antibiotics DIC could not be
controlled and she expired 4 days after development of
DIC. Transformation to MCL occurred 3 months after
evolution of secondary SM and her survival was
5 months following the diagnosis of MCL. The median
survival was 6 months in patients with MCL reported
in the literature [2].Conclusion
MCL occurring as a second neoplasia in association with
different MCs containing mixed orange and black color
round cytoplasmic granules, increased IL-6 levels and ac-
celerated phase of de novo CBL have not been reported in
the literature [1-3]. Neoplastic basophils with diffuse and
coarse basophilic granules as seen in Figure 2a in our pa-
tient possibly mimic neutrophils with toxic granules and
cause wrong characterization of neoplastic basophils as
neutrophils by the automated blood cell counters and mis-
leaded the physicians in making differential diagnosis.
Prophylactic leukapheresis should be considered as a pal-
liative treatment to reduce leukocyte count and cytokine
release from dead neoplastic cells induced by chemother-
apies in patients with leukemias associated with high
leukocyte counts and originating from the cells that are
known to produce and release cytokine such as MCs, eo-
sinophils [16] and neoplastic basophils [7]. In patients pre-
sented with recurrent attacks of fever and abdominal pain
associated with progressive leukocytosis, eosinophilia and
elevations in IL-6 and CRP levels, mastocytosis variants
[21], chronic myeloproliferative disorders [22], Castleman’s
disease [23] and possibility of underlying CBL [7] should
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ential count should be performed to rule out CBL.
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